TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06427785

Intervention type: DRUG
Intervention: Remimazolam besylate
Description: Thirty patients underwent elective lower extremity surgery receive spinal anesthesia, and then remimazolam besylate was given intravenously with an induction dose of 3mg/min. When the MOAA/S (Modified Observer's Assessment of Alertness/Sedation) score was ≤1, remimazolam besylate was maintained at 1mg/min for 24min, and finally stopped. Wavelet index, MOAA/S score, blood pressure, heart rate, respiratory rate, and pulse oxygen saturation were continuously monitored during the period.
Study: NCT06019650

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ECMAP
Description: The therapist will deliver 12-week training program comprised of 6 sessions at the participant's home/outpatient clinic depending upon the participants' choice within 3 months. The first two sessions will be offered weekly and then fortnightly.
Study: NCT06284811

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise program focusing on quadriceps
Description: Participants will be asked to perform the exercise program that focusing on quadriceps muscle

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise program focusing on quadriceps
Description: Participants will be asked to perform the exercise program that focusing on quadriceps muscle
Study: NCT05892354

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enteral immunonutrition
Description: Enteral immunonutrition (Oral Impact®, Nestle), 250ml/ bottle, 2 bottles per day, from 5 days before radiotherapy to the end of radiotherapy.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard enteral nutrition
Description: Isocaloric standard enteral nutrition formula (ENSURE®)， 250 mL per administration, 3 times per day. Preparation of the 250 mL dose involves adding 200 mL of potable water to a cup and slowly stirring in 52.7 g of ENSURE powder (approximately 6 scoops).
Study: NCT05497284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTP001
Description: LTP001 will be administered once daily in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to LTP001 will be administered once daily in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care (SoC)
Description: nintedanib, pirfenidone, or neither

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care (SoC)
Description: nintedanib, pirfenidone, or neither
Study: NCT04378244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DeltaRex-G
Description: This is an open label, dose-seeking phase 1/2 study using escalating doses of DeltaRex-G given intravenously for 7 days in a hospital setting.~The study will employ the standard Cohort of Three design (Storer, 1989). Three patients are treated at each dose level with expansion to six patients per cohort if DLT is observed in one of the three initially-enrolled patients at each dose level. If no DLT occurs in 3 patients, escalation to the next dose level will be permitted. The maximum tolerated dose is defined as the highest safely tolerated dose, where not more than one patient experienced DLT, with the next higher dose level having at least two patients who experienced DLT. No intra-patient dose escalation will take place. Patients who do not complete the 7-day treatment will be replaced.
Study: NCT04855708

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Office visit
Description: Patients randomized to this group will have a in-person 2-week post-operative visit
Study: NCT05784506

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Macronutrients
Description: Three successive food tolerance tests (glucose, protein and fat) at one-week intervals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed meal tolerance test (MMTT)
Description: Mixed meal tolerance test (MMTT)
Study: NCT05802238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Description: 1 gram of TXA in 10mg single-dose ampule (100mg/mL) administered 10 minutes prior to surgery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: control group will receive 10 mL of normal saline infused intravenously at 1 mL/min.
Study: NCT06393465

Intervention type: DRUG
Intervention: Tafamidis
Description: 61 milligrams under real world conditions
Study: NCT06295562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine 80mg combined with oxybutynin 5mg
Description: Atomoxetine 80mg combined with oxybutynin 5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine 37.5mg
Description: Venlafaxine 37.5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine 80mg combined with trazodone 100mg
Description: Atomoxetine 80mg combined with trazodone 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet
Study: NCT06383975

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsed field ablation with posterior wall isolation
Description: Extended pulmonary vein isolation including posterior wall isolation using pulsed field ablation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation and vein of Marshall ethanolization
Description: Radiofrequency pulmonary vein re-isolation (when necessary), vein of Marshall ethanol infusion with roof and mitral lines
Study: NCT06568692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCS6422 and capecitabine
Description: PCS6422 is an experimental drug that, when combined with capecitabine, may make the immune response more active against cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCS6422 and capecitabine
Description: PCS6422 is an experimental drug that, when combined with capecitabine, may make the immune response more active against cancer.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Commercially available capecitabine is a commonly used oral fluoropyrimidine.
Study: NCT06670820

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active rTMS
Description: iTBS targeting the left dorsolateral prefrontal cortex (DLPFC) per session, total10 sessions

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: sham iTBS targeting the left dorsolateral prefrontal cortex (DLPFC) per session, total 10 sessions
Study: NCT06670898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] NS-580
Description: Oral suspension
Study: NCT05424068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-person rehabilitaiton group
Description: participants who have chosen to complete the study intervention by coming in for their 8 week education and exercise sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual rehabilitation group
Description: Participants who have chosen to complete the study virtually instead of in-person sessions.
Study: NCT06669078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nal-lRl+Oxaliplain+5- FU +PD 1
Description: Nal-lRl+Oxaliplatin+5- FU +PD-1, these drugs are given on d1, d15, 28 days as one cycle, SBRT is performed during the third and fourth cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nal-lRl+Oxaliplain+5- FU
Description: Nal-lRl+Oxaliplatin+5- FU, these drugs are given on d1, d15, 28 days as one cycle.
Study: NCT04199091

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Craniosacral Therapy (CST) self-help techniques
Description: Manual self-help techniques based on Craniosacral Therapy (group setting).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Muscle Relaxation (PMR)
Description: Progressive muscle relaxation according to Jacobsen (group setting).
Study: NCT05601973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab is given at a fixed dose of 1750 mg (if baseline body weight is \<80 kg) or 2100 mg (if baseline body weight is ≥80 kg), i.v. every 3 weeks, until disease progression, or intolerable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib is given at a dose of 240 mg, orally, once daily. Treatment with lazertinib continues until disease progression or intolerable toxicities.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zirabev
Description: Bevacizumab (Zirabev®) is administered at a dose of 15mg/kg, i.v. every 3 weeks, until disease progression, or intolerable toxicity.
Study: NCT06476405

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Product A: Ploom® Non-Menthol Flavor
Description: Following randomization 4 subjects will be enclosed in the smoking chamber for 20 minutes, with the first 10 minutes not using any study product and for the second 10 minutes each subject uses one unit of the assigned study product (Product A: Ploom Non-menthol) ad libitum. Continuous measurement and recording of air and aerosol analytical endpoints will start immediately following the cohort entry into the chamber and end at the same ending time as the time-weighted- average endpoints.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Study Product B: Usual Brand Combustible Cigarette (UBCC) Non-Menthol Flavor
Description: Following randomization 4 subjects will be enclosed in the smoking chamber for 20 minutes, with the first 10 minutes not using any study product and for the second 10 minutes each subject uses one unit of the assigned study product (Product B: Non-menthol UBCC) ad libitum. Continuous measurement and recording of air and aerosol analytical endpoints will start immediately following the cohort entry into the chamber and end at the same ending time as the time-weighted- average endpoints.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Product C: Ploom® Menthol Heated Tobacco Product (HTP)
Description: Following randomization 4 subjects will be enclosed in the smoking chamber for 20 minutes, with the first 10 minutes not using any study product and for the second 10 minutes each subject uses one unit of the assigned study product (Product C: Ploom® Menthol HTP) ad libitum. Continuous measurement and recording of air and aerosol analytical endpoints will start immediately following the cohort entry into the chamber and end at the same ending time as the time-weighted- average endpoints.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Study Product D: Usual Brand Combustible Cigarette (UBCC) Menthol Flavor
Description: Following randomization 4 subjects will be enclosed in the smoking chamber for 20 minutes, with the first 10 minutes not using any study product and for the second 10 minutes each subject uses one unit of the assigned study product (Product D: Menthol UBCC) ad libitum. Continuous measurement and recording of air and aerosol analytical endpoints will start immediately following the cohort entry into the chamber and end at the same ending time as the time-weighted- average endpoints.
Study: NCT06321718

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PENG + LFCN block versus S-FICB
Description: 1. Group (A) will receive PENG + LFCN block:

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PENG + LFCN block versus S-FICB
Description: 1. Group (A) will receive PENG + LFCN block:
Study: NCT06776965

Intervention type: OTHER
Intervention: Dietary Questionnaire
Description: Self administered dietary questionnaire at baseline, 6 and 12 months.

Intervention type: OTHER
Intervention: Dietary Questionnaire
Description: Self administered dietary questionnaire at baseline, 6 and 12 months.

Intervention type: OTHER
Intervention: Dietary Questionnaire
Description: Self administered dietary questionnaire at baseline, 6 and 12 months.

Intervention type: OTHER
Intervention: Dietary Questionnaire
Description: Self administered dietary questionnaire at baseline, 6 and 12 months.

Intervention type: OTHER
Intervention: Evaluation of disease activity (DAS-28, ASDAS, EVA, number of swollen joints, number of painful joint, nocturnal pain, morning stiffness)
Description: Self administered questionnaire of disease activity at baseline, 6 and 12 months.

Intervention type: OTHER
Intervention: Evaluation of disease activity (DAS-28, ASDAS, EVA, number of swollen joints, number of painful joint, nocturnal pain, morning stiffness)
Description: Self administered questionnaire of disease activity at baseline, 6 and 12 months.

Intervention type: OTHER
Intervention: Evaluation of disease activity (DAS-28, ASDAS, EVA, number of swollen joints, number of painful joint, nocturnal pain, morning stiffness)
Description: Self administered questionnaire of disease activity at baseline, 6 and 12 months.

Intervention type: OTHER
Intervention: Evaluation of disease activity (DAS-28, ASDAS, EVA, number of swollen joints, number of painful joint, nocturnal pain, morning stiffness)
Description: Self administered questionnaire of disease activity at baseline, 6 and 12 months.
Study: NCT06240312

Intervention type: DEVICE
Group type: OTHER
Intervention: Images of eye at 2 eye pressures
Description: subject images of the eye's optic nerve head are studied
Study: NCT06300008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetylated fatty acid
Description: use approximately 3 cm long of cream per each side of knee, then apply on the operated knee until completely absorb

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: use approximately 3 cm long of cream per each side of knee, then apply on the operated knee until completely absorb
Study: NCT06177340

Intervention type: DEVICE
Intervention: visualization of the sacrospinous ligament
Description: visualization of the sacrospinous ligament by the Nanoscope system during sacrospinofixation
Study: NCT05903144

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual therapy
Description: manual diaphragmatic release technique combined with breathing exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: breathing exercise and prone position alone
Description: deep breathing exercise and prone position

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breathing exercise and prone position alone
Description: deep breathing exercise and prone position
Study: NCT05665777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qingyan Lihou Decoction
Description: Chinese medicine granules

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo granules
Study: NCT05784506

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed meal tolerance test (MMTT)
Description: Mixed meal tolerance test (MMTT)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed meal tolerance test (MMTT)
Description: Mixed meal tolerance test (MMTT)
Study: NCT05187403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod
Description: Eye-drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod
Description: Eye-drops

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eye-drops

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eye-drops
Study: NCT06138574

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: After the induction of general anesthesia, one group (Group: 1) will be administered dexmedotomidin infizyon and group (Group :2)remifentanil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil
Study: NCT05870280

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nurse coaching
Description: Group coaching will be applied to individuals with diabetes, 5-8 people.
Study: NCT05759234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS248 pieces
Description: The overall safety and tolerability of PI3Kγ inhibitor monotherapy for solid tumors is good, and it has shown preliminary clinical benefits. The safety of PI3Kγ inhibitor combined with immune checkpoint inhibitor is good, and the efficacy of single drug is significantly improved. Based on the evaluation of the safety and efficacy results of HS248 preclinical and clinical studies of similar PI3Kγ inhibitors, the benefits of this product outweigh the risks for patients with advanced solid tumors who have progressed through standard treatment, have toxicity intolerance, or have no standard treatment regimen. Sufficient to support planned clinical studies.
Study: NCT05227508

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BRIZO
Description: A capsule containing 400 mg. SC012 (unique soy extract)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Comprecel microcrystalline cellulose
Study: NCT04246034

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microvascular Breast Reconstruction with Vascularized Lymph Node Transfer
Description: simultaneous free abdominal flaps with VLNT from groin are transferred on a single pedicle for breast reconstruction and postmastectomy lymphedema
Study: NCT05685251

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Coaching
Description: Participants will receive a health coach telehealth/video visit or phone call every 2 weeks for 4 months, for a total of 8 calls. After these initial 8 calls, at approximately 6 months postpartum, the health coach will schedule maintenance calls 1 per month until approximately 12 months postpartum, for a total of 6 additional calls.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Blood Pressure Monitoring
Description: Participants will be provided an A\&D UA-651 (BT) home blood pressure monitor with an appropriate cuff size, they will be asked to take their blood pressure at least three days a week, 2 measurements each time
Study: NCT06338891

Intervention type: OTHER
Intervention: Main questionnaire
Description: Main questionnaire will evaluate the demographic and genetic characteristics, clinical manifestations, and self-perception of sensitivity to wheat or other food and the possible relationship between the intake of wheat or other foods and the flare-ups of the disease in FMF patients

Intervention type: OTHER
Intervention: Secondary questionnaire
Description: Secondary questionnaire will investigate the possible appearance of gastrointestinal and extraintestinal symptoms linked to the ingestion of gluten/wheat, which are not identifiable, by the patient, as FMF flare-ups, but might be compatible with a NCGS/NCWS diagnosis

Intervention type: OTHER
Intervention: Secondary questionnaire
Description: Secondary questionnaire will investigate the possible appearance of gastrointestinal and extraintestinal symptoms linked to the ingestion of gluten/wheat, which are not identifiable, by the patient, as FMF flare-ups, but might be compatible with a NCGS/NCWS diagnosis
Study: NCT06645509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTB gel (dose 1)
Description: A topical administration of Victorhy (TTB gel) to both hands, once daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTB gel (dose 2)
Description: A topical administration of Victorhy (TTB gel) to both hands, once daily for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A topical administration of a vehicle (Placebo) gel to both hands, once daily for 28 days
Study: NCT05531045

Intervention type: DIAGNOSTIC_TEST
Intervention: PET/CT
Description: FDG PET/CT assessed after 2 cycles of chemotherapy with PERCIST criteria
Study: NCT05032703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arm ergometer
Description: The conventional physical therapy program included three sets of exercises as follows:~Flexibility exercises to restore joint mobility of soft tissues. Static and dynamic balance exercise. Functional walking exercises.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arm ergometer
Description: The conventional physical therapy program included three sets of exercises as follows:~Flexibility exercises to restore joint mobility of soft tissues. Static and dynamic balance exercise. Functional walking exercises.
Study: NCT06535594

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Description: Laser acupuncture therapy will be performed five times a week for 4 weeks using laser beam. The acupoints on the ear that will be treated with laser acupuncture therapy are Zhouliao (LI12), Chize (LU5), Quchi (LI11), Shousanli (LI10) and Ashi.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: Physical therapy method involved six elbow joint exercises. Patients performed the six exercises sequentially under guidance, each exercise performed five times, three times a day, gradually increasing weight until the movement was effective but below the pain threshold.
Study: NCT05942313

Intervention type: DRUG
Intervention: Buprenorphine/ Methadone exposure
Description: Validate candidate genes- and prenatal opioid exposure- related maternal relapse and NOWS outcome associations in pregnant women and their newborns.
Study: NCT06104215

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BGT007H Injection
Description: BGT007H injection (d0) were infused intravenously once, and the dose group was 2.0× 10\^8 cells,5.0 ×10\^8 cells, 1.0× 10\^9 cells,3.0 × 10\^9 cells,6.0 ×10\^9 cells.
Study: NCT04993924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrorelix Acetate, Ganerelix Acetate
Description: 3-6 days of 0.25 mg starting on day 2-3 of the menstrual cycle
Study: NCT02233829

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brain Dopamine Reactivity
Description: IV methylphenidate, used under IND #124, 912 is injected into the subject s bloodstream to be used in conjunction with PET imaging to show displacement of \[11C\]raclopride.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brain Dopamine Reactivity
Description: IV methylphenidate, used under IND #124, 912 is injected into the subject s bloodstream to be used in conjunction with PET imaging to show displacement of \[11C\]raclopride.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Brain Dopamine Receptor
Description: The radiotracer \[11C\] raclopride is used for imaging dopamine receptors and dopamine release.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Brain Dopamine Receptor
Description: The radiotracer \[11C\] raclopride is used for imaging dopamine receptors and dopamine release.
Study: NCT05881200

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic mitohormesis
Description: The BIXEPS machine employs gentle pulsed magnetic signals specifically tuned to activate the natural powerhouse (mitochondria) within muscle. Brief 10-minute MM sessions with the device recreate similar biological and metabolic effects as exercise, but without physical stress or strain. It is intended to improve the strength and function of users, promoting overall fitness and well-being. Just like exercise, these effects accumulate with time.~Subjects will receive 12 sessions of 10 minute treatments